Refine
Has Fulltext
- yes (18)
Is part of the Bibliography
- yes (18)
Document Type
- Journal article (16)
- Doctoral Thesis (2)
Keywords
- biodiversity (3)
- arthropods (2)
- 28 (1)
- ALS (1)
- ARONJ (1)
- ATM (1)
- Ampicillin (1)
- Angst (1)
- Arthropod (1)
- Berger-Parker (1)
Institute
- Theodor-Boveri-Institut für Biowissenschaften (10)
- Klinik und Poliklinik für Strahlentherapie (3)
- Pathologisches Institut (3)
- Klinik und Poliklinik für Mund-, Kiefer- und Plastische Gesichtschirurgie (2)
- Comprehensive Cancer Center Mainfranken (1)
- Institut für Anorganische Chemie (1)
- Institut für Experimentelle Biomedizin (1)
- Institut für Geographie und Geologie (1)
- Institut für Hygiene und Mikrobiologie (1)
- Institut für Pharmazie und Lebensmittelchemie (1)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 101003595 (1)
Squamous cell carcinomas (SCC) frequently have an exceptionally high mutational burden. As consequence, they rapidly develop resistance to platinum-based chemotherapy and overall survival is limited. Novel therapeutic strategies are therefore urgently required. SCC express ∆Np63, which regulates the Fanconi Anemia (FA) DNA-damage response in cancer cells, thereby contributing to chemotherapy-resistance. Here we report that the deubiquitylase USP28 is recruited to sites of DNA damage in cisplatin-treated cells. ATR phosphorylates USP28 and increases its enzymatic activity. This phosphorylation event is required to positively regulate the DNA damage repair in SCC by stabilizing ∆Np63. Knock-down or inhibition of USP28 by a specific inhibitor weakens the ability of SCC to cope with DNA damage during platin-based chemotherapy. Hence, our study presents a novel mechanism by which ∆Np63 expressing SCC can be targeted to overcome chemotherapy resistance. Limited treatment options and low response rates to chemotherapy are particularly common in patients with squamous cancer. The SCC specific transcription factor ∆Np63 enhances the expression of Fanconi Anemia genes, thereby contributing to recombinational DNA repair and Cisplatin resistance. Targeting the USP28-∆Np63 axis in SCC tones down this DNA damage response pathways, thereby sensitizing SCC cells to cisplatin treatment.
Lung cancer is the most common cancer worldwide and the leading cause of cancer-related deaths in both men and women. Despite the development of novel therapeutic interventions, the 5-year survival rate for non-small cell lung cancer (NSCLC) patients remains low, demonstrating the necessity for novel treatments. One strategy to improve translational research is the development of surrogate models reflecting somatic mutations identified in lung cancer patients as these impact treatment responses. With the advent of CRISPR-mediated genome editing, gene deletion as well as site-directed integration of point mutations enabled us to model human malignancies in more detail than ever before. Here, we report that by using CRISPR/Cas9-mediated targeting of Trp53 and KRas, we recapitulated the classic murine NSCLC model Trp53fl/fl:lsl-KRasG12D/wt. Developing tumors were indistinguishable from Trp53fl/fl:lsl-KRasG12D/wt-derived tumors with regard to morphology, marker expression, and transcriptional profiles. We demonstrate the applicability of CRISPR for tumor modeling in vivo and ameliorating the need to use conventional genetically engineered mouse models. Furthermore, tumor onset was not only achieved in constitutive Cas9 expression but also in wild-type animals via infection of lung epithelial cells with two discrete AAVs encoding different parts of the CRISPR machinery. While conventional mouse models require extensive husbandry to integrate new genetic features allowing for gene targeting, basic molecular methods suffice to inflict the desired genetic alterations in vivo. Utilizing the CRISPR toolbox, in vivo cancer research and modeling is rapidly evolving and enables researchers to swiftly develop new, clinically relevant surrogate models for translational research.
Aim: Despite increasing interest in β-diversity, that is the spatial and temporal turnover of species, the mechanisms underlying species turnover at different spatial scales are not fully understood, although they likely differ among different functional groups. We investigated the relative importance of dispersal limitations and the environmental filtering caused by vegetation for local, multi-taxa forest communities differing in their dispersal ability, trophic position and body size.
Location: Temperate forests in five regions across Germany.
Methods: In the inter-region analysis, the independent and shared effects of the regional spatial structure (regional species pool), landscape spatial structure (dispersal limitation) and environmental factors on species turnover were quantified with a 1-ha grain across 11 functional groups in up to 495 plots by variation partitioning. In the intra-region analysis, the relative importance of three environmental factors related to vegetation (herb and tree layer composition and forest physiognomy) and spatial structure for species turnover was determined.
Results: In the inter-region analysis, over half of the explained variation in community composition (23% of the total explained 35%) was explained by the shared effects of several factors, indicative of spatially structured environmental filtering. Among the independent effects, environmental factors were the strongest on average over 11 groups, but the importance of landscape spatial structure increased for less dispersive functional groups. In the intra-region analysis, the independent effect of plant species composition had a stronger influence on species turnover than forest physiognomy, but the relative importance of the latter increased with increasing trophic position and body size.
Main conclusions: Our study revealed that the mechanisms structuring assemblage composition are associated with the traits of functional groups. Hence, conservation frameworks targeting biodiversity of multiple groups should cover both environmental and biogeographical gradients. Within regions, forest management can enhance β-diversity particularly by diversifying tree species composition and forest physiognomy.
Head and neck squamous cell carcinoma (HNSCC) is known to overexpress a variety of receptor tyrosine kinases, such as the HGF receptor Met. Like other malignancies, HNSCC involves a mutual interaction between the tumor cells and surrounding tissues and cells. We hypothesized that activation of HGF/Met signaling in HNSCC influences glucose metabolism and therefore substantially changes the tumor microenvironment. To determine the effect of HGF, we submitted three established HNSCC cell lines to mRNA sequencing. Dynamic changes in glucose metabolism were measured in real time by an extracellular flux analyzer. As expected, the cell lines exhibited different levels of Met and responded differently to HGF stimulation. As confirmed by mRNA sequencing, the level of Met expression was associated with the number of upregulated HGF-dependent genes. Overall, Met stimulation by HGF leads to increased glycolysis, presumably mediated by higher expression of three key enzymes of glycolysis. These effects appear to be stronger in Met\(^{high}\)-expressing HNSCC cells. Collectively, our data support the hypothesized role of HGF/Met signaling in metabolic reprogramming of HNSCC.
Biodiversity, a multidimensional property of natural systems, is difficult to quantify partly because of the multitude of indices proposed for this purpose. Indices aim to describe general properties of communities that allow us to compare different regions, taxa, and trophic levels. Therefore, they are of fundamental importance for environmental monitoring and conservation, although there is no consensus about which indices are more appropriate and informative. We tested several common diversity indices in a range of simple to complex statistical analyses in order to determine whether some were better suited for certain analyses than others. We used data collected around the focal plant Plantago lanceolata on 60 temperate grassland plots embedded in an agricultural landscape to explore relationships between the common diversity indices of species richness (S), Shannon's diversity (H'), Simpson's diversity (D-1), Simpson's dominance (D-2), Simpson's evenness (E), and Berger-Parker dominance (BP). We calculated each of these indices for herbaceous plants, arbuscular mycorrhizal fungi, aboveground arthropods, belowground insect larvae, and P.lanceolata molecular and chemical diversity. Including these trait-based measures of diversity allowed us to test whether or not they behaved similarly to the better studied species diversity. We used path analysis to determine whether compound indices detected more relationships between diversities of different organisms and traits than more basic indices. In the path models, more paths were significant when using H', even though all models except that with E were equally reliable. This demonstrates that while common diversity indices may appear interchangeable in simple analyses, when considering complex interactions, the choice of index can profoundly alter the interpretation of results. Data mining in order to identify the index producing the most significant results should be avoided, but simultaneously considering analyses using multiple indices can provide greater insight into the interactions in a system.
Synthese siliciumhaltiger Wirkstoffe und Synthese-Bausteine des 4-Silapiperidin-Typs:
Im Rahmen der systematischen Untersuchungen unseres Arbeitskreises zur C/Si-Bioisosterie wurde für bereits bekannte σ-Rezeptor-Antagonisten eine neue verbesserte Syntheseroute entwickelt, wobei die Endprodukte jeweils in einer sechsstufigen Synthese dargestellt und als entsprechende Hydrochloride isoliert wurden.
Ein weiteres Teilprojekt der vorliegenden Arbeit betraf die Entwicklung einer Syntheseroute zur Darstellung von Sila-L-741,626, dem Sila-Analogon des selektiven D2-Dopamin-Rezeptorantagonisten L-741,626.
In einem weiteren Teilprojekt der vorliegenden Arbeit wurde ein neuer, säurefreier Weg zu 4 Silapiperidin-Bausteinen mit NH-Funktion entwickelt, der eine Staudinger-Reaktion als ringschließenden Syntheseschritt beinhaltet. Am Beispiel einer Modellverbindung, die in zwei alternativen jeweils fünfstufigen Synthesen ausgehend von Dichlordiphenylsilan dargestellt und als Hydrochlorid isoliert wurde, konnte die neue Syntheseroute erfolgreich ausgearbeitet werden. Die anhand der Modellverbindung erfolgreich getestete Syntheseroute konnte im Folgenden auf ein Zielmolekül angewendet werden, das anstatt einer inerten Phenyl-Gruppe die säurelabilere 4-Methoxyphenyl- (MOP-) Gruppe trägt.
Synthese siliciumhaltiger Wirkstoffe und Synthese-Bausteine des 4-Silacyclohexan-1-on- und (4-Silacyclohexan-1-yl)amin-Typs:
Im Zusammenhang mit unseren systematischen Untersuchungen zur C/Si-Bioisosterie wurde Sila-pramiverin dargestellt. Dies gelang in einer vierstufigen Synthese, ausgehend von Dichlordiphenylsilan. Im Zuge dieser Synthese fand Brown’s DCME-Prozess Anwendung, um in einer Eintopf-Reaktion das entsprechende 4-Silacyclohexan-1-on und daraus durch anschließende reduktive Aminierung mit Isopropylamin Sila-pramiverin erstmals darzustellen.
Analog zur Synthese von Sila-pramiverin konnten ebenfalls Synthese-Bausteine des 4 Silacyclohexan-1-on-Typs sowie des (4-Silacyclohexan-1-yl)amin-Typs unter Verwendung der 4 Methoxyphenyl- (MOP ), 2,6-Dimethoxyphenyl- (DMOP-) bzw. 2,4,6-Trimethoxyphenyl- (TMOP-) Schutzgruppe dargestellt werden.
In einer Machbarkeitsstudie wurde zudem unter selektiver Abspaltung der 4 Methoxyphenyl- (MOP ), 2,6-Dimethoxyphenyl- (DMOP-) bzw. 2,4,6-Trimethoxyphenyl- (TMOP-) Schutzgruppe der phenylierten 4 Silacyclohexan-1-one mittels Chlorwasserstoff das entsprechende Chlorsilan dargestellt.
Synthese siliciumhaltiger Synthese-Bausteine des 4-Silatetrahydropyran-Typs:
Eine fast gänzlich unerforschte Klasse siliciumhaltiger Heterocyclen stellen 4 Silatetrahydropyrane dar. Im Rahmen der vorliegenden Arbeit konnte zunächst anhand einer Modellstudie das 4,4-Diphenyl-4-silatetrahydropyran dargestellt werden. Die für die Modellverbindung ausgearbeitete Syntheseroute konnte schließlich auf die Synthese der 4 Methoxyphenyl- (MOP-) und 2,6-Dimethoxyphenyl- (DMOP-) substituierten 4 Silatetra¬hydropyrane übertragen werden. Diese konnten jeweils in einer vierstufigen Synthese dargestellt werden. Lediglich die Synthese der 2,4,6-Trimethoxyphenyl- (TMOP-) substituierten 4 Silatetra¬hyropyrane gelang aufgrund der Instabilität der mesylierten Zwischenstufen nicht.
Background
Acute respiratory distress syndrome (ARDS) is a complex clinical diagnosis with various possible etiologies. One common feature, however, is pulmonary permeability edema, which leads to an increased alveolar diffusion pathway and, subsequently, impaired oxygenation and decarboxylation. A novel inhaled peptide agent (AP301, solnatide) was shown to markedly reduce pulmonary edema in animal models of ARDS and to be safe to administer to healthy humans in a Phase I clinical trial. Here, we present the protocol for a Phase IIB clinical trial investigating the safety and possible future efficacy endpoints in ARDS patients.
Methods
This is a randomized, placebo-controlled, double-blind intervention study. Patients with moderate to severe ARDS in need of mechanical ventilation will be randomized to parallel groups receiving escalating doses of solnatide or placebo, respectively. Before advancing to a higher dose, a data safety monitoring board will investigate the data from previous patients for any indication of patient safety violations. The intervention (application of the investigational drug) takes places twice daily over the course of 7 days, ensued by a follow-up period of another 21 days.
Discussion
The patients to be included in this trial will be severely sick and in need of mechanical ventilation. The amount of data to be collected upon screening and during the course of the intervention phase is substantial and the potential timeframe for inclusion of any given patient is short. However, when prepared properly, adherence to this protocol will make for the acquisition of reliable data. Particular diligence needs to be exercised with respect to informed consent, because eligible patients will most likely be comatose and/or deeply sedated at the time of inclusion.
Trial registration
This trial was prospectively registered with the EU Clinical trials register (clinicaltrialsregister.eu). EudraCT Number: 2017-003855-47.
The body has the capacity to compensate for an occluded artery by creating a natural bypass upon increased fluid shear stress. How this mechanical force is translated into collateral artery growth (arteriogenesis) is unresolved. We show that extravasation of neutrophils mediated by the platelet receptor GPIbα and uPA results in Nox2-derived reactive oxygen radicals, which activate perivascular mast cells. These c-kit+/CXCR-4+ cells stimulate arteriogenesis by recruiting additional neutrophils as well as growth-promoting monocytes and T cells. Additionally, mast cells may directly contribute to vascular remodeling and vascular cell proliferation through increased MMP activity and by supplying growth-promoting factors. Boosting mast cell recruitment and activation effectively promotes arteriogenesis, thereby protecting tissue from severe ischemic damage. We thus find that perivascular mast cells are central regulators of shear stress-induced arteriogenesis by orchestrating leukocyte function and growth factor/cytokine release, thus providing a therapeutic target for treatment of vascular occlusive diseases.
Highly efficient single-photon sources (SPS) can increase the secure key rate of quantum key distribution (QKD) systems compared to conventional attenuated laser systems. Here we report on a free space QKD test using an electrically driven quantum dot single-photon source (QD SPS) that does not require a separate laser setup for optical pumping and thus allows for a simple and compact SPS QKD system. We describe its implementation in our 500 m free space QKD system in downtown Munich. Emulating a BB84 protocol operating at a repetition rate of 125 MHz, we could achieve sifted key rates of 5-17 kHz with error ratios of 6-9% and g((2))(0)-values of 0.39-0.76.
Background: Pioglitazone, an oral anti-diabetic that stimulates the PPAR-gamma transcription factor, increased survival of mice with amyotrophic lateral sclerosis (ALS).
Methods/Principal Findings: We performed a phase II, double blind, multicentre, placebo controlled trial of pioglitazone in ALS patients under riluzole. 219 patients were randomly assigned to receive 45 mg/day of pioglitazone or placebo (one: one allocation ratio). The primary endpoint was survival. Secondary endpoints included incidence of non-invasive ventilation and tracheotomy, and slopes of ALS-FRS, slow vital capacity, and quality of life as assessed using EUROQoL EQ-5D. The study was conducted under a two-stage group sequential test, allowing to stop for futility or superiority after interim analysis. Shortly after interim analysis, 30 patients under pioglitazone and 24 patients under placebo had died. The trial was stopped for futility; the hazard ratio for primary endpoint was 1.21 (95% CI: 0.71-2.07, p = 0.48). Secondary endpoints were not modified by pioglitazone treatment. Pioglitazone was well tolerated.
Conclusion/Significance: Pioglitazone has no beneficial effects on the survival of ALS patients as add-on therapy to riluzole.